HZNP Insider Trading Activity and SEC Form 4 Filings
HZNP insider trading summary
No open-market insider purchases or sales of Horizon Therapeutics Public Ltd Co (HZNP) have been reported on SEC Form 4 in the past 12 months.
Latest HZNP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 17, 2023 | Andy Pasternak | EVP, Chief Strategy Officer | Sell | $3.1M (27,129 @ $113.03) |
| Jan 13, 2023 | Aaron Cox | EVP, Chief Financial Officer | Sell | $4.1M (36,148 @ $113.17) |
| Jan 11, 2023 | Jeffrey W Sherman | EVP and Chief Medical Officer | Sell | $381K (3,368 @ $113.10) |
| Jan 10, 2023 | Jeffrey W Sherman | EVP and Chief Medical Officer | Sell | $381K (3,368 @ $113.05) |
| Jan 6, 2023 | Jeffrey W Sherman | EVP and Chief Medical Officer | Sell | $588K (5,187 @ $113.29) |
| Dec 13, 2022 | Andy Pasternak | EVP, Chief Strategy Officer | Sell | $779K (6,918 @ $112.60) |
| Dec 13, 2022 | Andy Pasternak | EVP, Chief Strategy Officer | Sell | $2.6M (23,251 @ $112.61) |
| Dec 12, 2022 | Jeffrey W Sherman | EVP and Chief Medical Officer | Sell | $2.4M (21,378 @ $111.45) |
| Dec 12, 2022 | Jeffrey W Sherman | EVP and Chief Medical Officer | Sell | $777K (6,974 @ $111.44) |
| Aug 4, 2022 | Sean M. Clayton | EVP, General Counsel | Buy | $50K (745 @ $66.67) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.